Jesse Feierabend-Peters, MD, PhD and Hugh Silk, MD, MPH
Despite availability of good national oral health curricula for medical trainees, most physicians are ill-equipped to identify oral cancers or avoid unnecessary referrals.
AMA J Ethics. 2022;24(1):E19-26. doi:
10.1001/amajethics.2022.19.
During one 2014 Ebola epidemic, arrival of “safe burial” teams was often delayed. Some buried their loved ones themselves, which undermined containment efforts.
AMA J Ethics. 2020;22(1):E5-9. doi:
10.1001/amajethics.2020.5.
Victoire Fokom Defo, MD and Joël Fokom Domgue, MD, MPH
HPV tests are alternatives to Pap smear screening that enable women to self-collect specimens and might be the best cervical cancer prevention strategy for many.
AMA J Ethics. 2020;22(2):E116-125. doi:
10.1001/amajethics.2020.116.
Sofie Layton, MRes, Jo Wray, PhD, Victoria Walsh, PhD, and Giovanni Biglino, PhD
Based on an artist’s, bioengineer’s, and health psychologist’s reflections on pediatric and adult group workshop practice settings, this article suggests 8 dimensions of risk that deserve ethical attention.
AMA J Ethics. 2022;24(7):E638-645. doi:
10.1001/amajethics.2022.638.
Artist and researcher Dr Mark Gilbert joins Ethics Talk to discuss arts-based research: what it is, who it’s for, and why we should pay closer attention to it as a method of clinical inquiry.
Aislinn C. Rookwood and Mariah Abney join Ethics Talk to discuss their article, coauthored with Hannah S. Butler-Robbins, Danielle Marie Westmark, and Dr Regina Idoate: “Arts-Based Research Methods to Explore Cancer in Indigenous Communities.”
Sofie Layton joins Ethics Talk to discuss her article, coauthored with Drs Jo Wray, Victoria Walsh, and Giovanni Biglino: “What Arts-and-Health Practices Teach Us About Participation, Re-presentation, and Risk.”
Barriers to effective prognosis conversations include knowledge deficits, misconceptions, cultural differences, and lack of motivation. These can be addressed head-on by good communication interventions.
AMA J Ethics. 2018;20(8):E757-765. doi:
10.1001/amajethics.2018.757.
Thomas W. LeBlanc, MD, MA, MHS and Arif H. Kamal, MD, MBA, MHS
Clinical trials should assess patients’ distress and test interventions to address it, just as they assess adverse events and test novel therapeutic agents.
AMA J Ethics. 2017;19(5):460-466. doi:
10.1001/journalofethics.2017.19.5.stas1-1705.